Overview of antidepressants currently used to treat anxiety disorders

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 22, 1999, Pages 18-22

  Feighner, John P ^a  

^a Feighner Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; IMIPRAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; ALPRAZOLAM; AZAPIRONE; BUSPIRONE; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE MALEATE; NEFAZODONE; PAROXETINE; SERTRALINE; TRAZODONE; UNCLASSIFIED DRUG;

ANXIETY NEUROSIS; ARTICLE; DEPRESSION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; OBSESSION; PANIC; PRIORITY JOURNAL; ANXIETY DISORDER; COMORBIDITY; DELAYED RELEASE FORMULATION; PSYCHOLOGICAL ASPECT; REVIEW; BODY WEIGHT DISORDER; CONSTIPATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; INSOMNIA;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY DISORDERS; COMORBIDITY; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER; HUMANS; MONOAMINE OXIDASE INHIBITORS; SEROTONIN UPTAKE INHIBITORS;

EID: 0033378891     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety 1996-1997;4:160-168
2. Kuzel RJ. Treating comorbid depression and anxiety. J Fam Pract 1996;43: S45-S53
3. Casacalenda N, Boulenger J-P. Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications. Can J Psychiatry 1998;43:722-730
4. Goldberg RJ. Diagnostic dilemmas presented by patients with anxiety and depression. Am J Med 1995;98:278-284
5. Fawcett J, Kravitz HM. Anxiety syndromes and their relationship to depressive illness. J Clin Psychiatry 1983;44(8, sec 2):8-11
6. Hamilton M. The clinical distinction between anxiety and depression. Br J Clin Pharmacol 1983;15(suppl 2):165S-169S
7. Kessler RC, Nelson CB, McGonagle KA, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry 1996;168(suppl 30):17-30
8. Lesse S. The relationship of anxiety to depression. Am J Psychother 1982; 36:332-349
9. Paul SM. Anxiety and depression: a common neurobiological substrate? J Clin Psychiatry 1988;49(10, suppl):13-16
10. Leckman JF, Weisman MM, Merikangas KR, et al. Panic disorder and major depression: increased risk of depression, alcoholism, panic, and phobic disorders in families of depressed probands with panic disorder. Arch Gen Psychiatry 1983;40:1055-1060
11. Rocca P, Fonzo V, Scotta M, et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997;95:444-450
12. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazocone, and diazepam. Arch Gen Psychiatry 1993;50: 884-895
13. Keller MB, Lavori PW, Goldenberg IM, et al. Influence of depression on the treatment of panic disorder with imipramine, alprazolam and placebo. J. Affect Disord 1993;28:27-38
14. Lydiard RB, Laraia MT, Ballenger JC, et al. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry 1987;44:664-665
15. Sheehan DV, Raj AB, Sheehan KH, et al. Is buspirone effective for panic disorder? J Clin Psychopharmacol 1990;10:3-11
16. Sussman N. Anxiolytic antidepressant augmentation. J Clin Psychiatry 1998;59(suppl 5):42-48
17. Taylor CB. Treatment of anxiety disorders. In: Schatzberg AF, Nemeroff CB, eds. American Psychiatric Press Textbook of Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press; 1998:775-789
18. Lydiard RB, Brawman-Mintzer O, Ballenger JC. Recent developments in the psychopharmacology of anxiety disorders. J Consult Clin Psychol 1996;64:660-668
19. DeVeaugh-Geiss J, Landau P, Katz R. Treatment of obsessive compulsive disorder with clomipramine. Psychiatr Ann 1989;19:97-101
20. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991; 48:730-738
21. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 1988;44:293-301
22. Noyes R Jr, Perry P. Maintenance treatment with antidepressants in panic disorder. J Clin Psychiatry 1990;51(12, suppl A):24-30
23. Cesura AM, Pletscher A. The new generation of monoamine oxidase inhibitors. Prog Drug Res 1992;38:171-297
24. Liebowitz MR, Quitkin FM, Stewart JW, et al. Phenelzine vs imipramine in atypical depression: a preliminary report. Arch Gen Psychiatry 1984;41: 669-677
25. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-137
26. Quitkin FM, McGrath PJ, Stewart JW, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Arch Gen Psychiatry 1990;47:935-941
27. Tiller JWG, Bouwer C, Behnke K. Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder. Int Clin Psychopharmacol 1997;12(suppl 6):S27-S30
28. Chouinard G. Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies. Int Clin Psychopharmacol 1992;7:37-41
29. Davidson JRT. Pharmacotherapy of social anxiety disorder. J Clin Psychiatry 1998;59(suppl 17):47-51
30. Goodman WK, Price LH, Rasmussen SA, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder. Arch Gen Psychiatry 1989;46:36-44
31. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995; 152:1368-1376
32. Sheehan D, Dunbar GC, Fuell DL. The effect of paroxetine on anxiety and agitation associated with depression. Psychopharmacol Bull 1992;28: 139-143
33. den Boer JA, Westenberg HGM, De Leeuw AS, et al. Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine. Int Clin Psychopharmacol 1995;9(suppl 4):47-52
34. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995;52:53-60
35. Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994;55: 406-413
36. Kehoe WA, Schorr RB. Focus on mirtazapine: a new antidepressant with noradrenergic and specific serotonergic activity. Formulary 1996;31: 455-469
37. Sitsen JMA, Moors J. Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms: results from a placebo-controlled trial. Drug Invest 1994;8:339-344
38. Fawcett J, Barkin RL. Meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998;59: 123-127
39. DeVane CL. Nefazodone: pharmacology and efficacy of a new antidepressant agent: formulary considerations. Pharm Ther 1995;20:363-374
40. Taylor DP, Carter RB, Eison AS, et al. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 1995;56 (suppl 6):3-11
41. Fontaine R, Ontiveros A, Elie R, et al. Double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994;55:234-241
42. Zajecka JM. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. J Clin Psychiatry 1996;57(suppl 2):10-14
43. Hedges DW, Reimherr FW, Strong RE, et al. An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharmacol Bull 1996;32:671-676
44. Muth EA, Moyer JA, Haskins JT, et al. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991;23:191-199
45. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 1998;47:55-62
46. Haskins JT, Rudolph R. Aguiar L, et al. Venlafaxine XR is an efficacious short-and long-term treatment for generalized anxiety disorder. Presented at the 11th annual meeting of the European College of Neuropsychopharmacology; Oct 31-Nov 4, 1998; Paris, France
47. Haskins T, Rudolph R, Pallay A, et al. Double-blind, placebo-controlled study of once daily venlafaxine XR in outpatients with generalized anxiety disorder (GAD). Presented at the 21st meeting of the Collegium Internationale Neuro-Psychopharmacologicum; July 12-16, 1998; Glasgow, Scotland
48. Davidson JRT, DuPont RL, Hedges D, et al. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999;60:528-535
49. Hackett D, Parks V, Salinas E. A 6-month evaluation of 3 dose levels of venlafaxine extended-release in non-depressed outpatients with generalized anxiety disorder. Presented at the 19th annual conference of the Anxiety Disorders Association of America; March 25-28, 1999; San Diego, Calif
50. Khan A, Upton GV, Rudolph RL, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychopharmacol 1998;18:19-25
51. Rudolph RL, Entsuah R, Chitra R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol 1998;18:136-144